Table 2. Estimates of effects on general and current health by experimental immune activation with LPS versus placebo, and time.
| Intercept | Condition (LPS) b (95% CI) |
Time1 (1,5h vs. pre injection) b (95% CI) |
Time2 (4.5/5h vs. pre injection) b (95% CI) |
Condition×Time1 (1.5h) b (95% CI) |
Condition×Time2 (4.5h/5h) b (95% CI) |
|
|---|---|---|---|---|---|---|
| General health (Experiment 1) | 4.63 (4.15;5.10) | 0.00 (-0.62;0.62) | 0.13 (-0.50;0.75) | -0.13 (-0.75;0.50) | -1.88 (-2.76;-0.99)*** | -1.10 (-2.00;-0.20)* |
| Current health (Experiment 1) | 6.64 (6.16;7.09) | -0.25 (-1.05;0.55) | 0.00 (-0.65;0.65) | -0.38 (-0.99;0.24) | -3.00 (-4.44; -1.56)*** | -1.59 (-2.87;-0.31)* |
| Current health (Experiment 2) | 6.24 (5.77;6.70) | 0.02 (-0.39;0.43) | -0.62 (-1.09; -0.15)* | -0.22 (-0.70;0.26) | -1.79 (-2.47; -1.10)*** | -0.91 (-1.56;-0.25)*** |
Estimates presented as mixed regression model (b) coefficients (95%CI). The intercept corresponds to mean health in the placebo group at baseline. The fixed effect (condition) represents any differences in health from that of the placebo group at baseline. The interaction effects accounts for differences between conditions at peak inflammation (1.5h after injection and at the end of experiment; 4.5 h after injection for Experiment 1 and at 5 h for Experiment 2). The fixed effects presented are adjusted for all other effects included in the model.
*p < .05,
***p < .001;
p-values based on 2000 bootstrap repetitions. LPS = lipopolysaccharide.